Lifecore Biomedical, a Minnesota-based contract development and manufacturing organization (CDMO) specializing in sterile injectable products, has signed an agreement with an undisclosed global pharmaceutical company to transfer a commercially marketed injectable drug product into its production pipeline.

Under the agreement, Lifecore will provide technical transfer services to support future commercial manufacturing of the injectable therapy. The CDMO said the program is expected to become one of its largest contracts and is projected to begin contributing commercial revenue in 2028.

According to Lifecore, the product involves a complex, high-viscosity formulation that aligns with the company’s expertise in technically challenging injectable manufacturing processes. The agreement marks the CDMO’s seventh late-stage commercial program and the eleventh program added to its pipeline in 2026.

The new contract expands Lifecore’s relationship with global pharmaceutical customers as it continues to grow its sterile injectable CDMO business. According to the company, its late-stage pipeline now includes 13 programs with the potential to generate commercial revenue by the end of 2028.

The announcement follows recent updates from Lifecore highlighting anticipated growth in fill-finish manufacturing demand. During its second-quarter earnings call in August, the company said contractually committed fill-finish demand from its largest customer is expected to double beginning in 2027 compared with 2026 levels and increase by more than 200% in 2028.

Lifecore operates a GMP-ready isolator filling line for vials, cartridges, and prefilled syringes that more than doubled its sterile injectable production capacity. The CDMO said it expects capacity utilization to increase as development programs advance toward commercialization and existing customer commitments ramp up over the coming years.

The company has also continued to add new customer programs across commercial, late-stage and early-stage development. Several recently announced agreements include technology transfer, process performance qualification, and GMP readiness activities intended to support future product launches and commercial manufacturing opportunities.